Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
AstraZeneca Pharma India Limited (ASTRAZEN.NS)
Bengaluru, IN
AstraZeneca Pharma India Limited operates as a biopharmaceutical entity, engaged in the development, production, and global commercialization of pharmaceutical products, serving both the Indian domestic market and international clientele. The company offers an extensive range of medications, including treatments for cardiovascular conditions and diabetes, marketed under brands such as Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN. Its respiratory portfolio features products like Symbicort and FASENRA, while its oncology division provides various cancer therapies, including LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex. Furthermore, the firm extends its product line to encompass therapeutic solutions for renal, metabolic, and immunological disorders. Beyond its pharmaceutical offerings, AstraZeneca Pharma India Limited also provides clinical trial services. Established in 1979, the company is based in Bengaluru, India, and functions as a subsidiary of AstraZeneca Pharmaceuticals AB.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.51% | +0.68% | +0.87% | -2.27% | -3.88% | -4.22% | +9.39% | +165.95% | +127.65% | +715.31% | +29,017.85% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+32.8% ★ Q1'26: +21.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+62.0% ★ Q1'26: -23.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-1.2% Q1'26: -11.4% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+10.3% Q1'26: +9.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+32.5% ★ Q1'26: +31.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.42× ★ Q1'26: 0.45× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
8.32B
est: 8.38B (-0.8%)
|
8.09B
est: 9.07B (-10.8%)
|
8.06B
est: 10.06B (-20.0%)
|
10.03B
est: 11.03B (-9.0%)
|
12.96B
est: 12.08B (+7.2%)
|
8.38B
8.38B – 8.38B
-30.6% YoY
|
8.38B
8.38B – 8.38B
+0.0% YoY
|
9.07B
9.07B – 9.07B
+8.1% YoY
|
10.06B
10.06B – 10.06B
+11.0% YoY
|
| EBITDA |
1.34B
est: 1.27B (+5.5%)
|
1.48B
est: 1.37B (+7.9%)
|
1.01B
est: 1.52B (-33.7%)
|
1.51B
est: 1.88B (-19.8%)
|
2.36B
est: 2.07B (+14.0%)
|
1.27B
1.27B – 1.27B
-38.7% YoY
|
1.27B
1.27B – 1.27B
+0.0% YoY
|
1.37B
1.37B – 1.37B
+8.1% YoY
|
1.52B
1.52B – 1.52B
+11.0% YoY
|
| EBIT |
1.15B
est: 1.11B (+4.1%)
|
1.28B
est: 1.20B (+7.2%)
|
839.90M
est: 1.33B (-36.7%)
|
1.35B
est: 1.35B (-0.1%)
|
2.21B
est: 1.60B (+37.8%)
|
1.11B
1.11B – 1.11B
-30.9% YoY
|
1.11B
1.11B – 1.11B
+0.0% YoY
|
1.20B
1.20B – 1.20B
+8.1% YoY
|
1.33B
1.33B – 1.33B
+11.0% YoY
|
| Net Income |
722.10M
est: 833.43M (-13.4%)
|
933.00M
est: 807.69M (+15.5%)
|
616.00M
est: 912.68M (-32.5%)
|
992.90M
est: 949.79M (+4.5%)
|
1.62B
est: 1.04B (+54.9%)
|
833.47M
833.47M – 833.47M
-20.0% YoY
|
833.47M
833.47M – 833.47M
+0.0% YoY
|
807.72M
807.72M – 807.72M
-3.1% YoY
|
912.71M
912.71M – 912.71M
+13.0% YoY
|
| SGA |
2.20B
est: 824.49M (+166.3%)
|
2.23B
est: 891.64M (+149.7%)
|
2.35B
est: 4.28B (-45.2%)
|
2.61B
est: 4.69B (-44.3%)
|
2.47B
est: 1.19B (+107.1%)
|
1.96B
1.96B – 1.96B
+64.1% YoY
|
1.96B
1.96B – 1.96B
+0.0% YoY
|
2.12B
2.12B – 2.12B
+8.1% YoY
|
2.35B
2.35B – 2.35B
+11.0% YoY
|
| EPS |
28.88
est: 33.34 (-13.4%)
|
37.32
est: 32.31 (+15.5%)
|
24.64
est: 36.51 (-32.5%)
|
39.72
est: 38.32 (+3.7%)
|
64.60
est: 40.22 (+60.6%)
|
33.34
33.34 – 33.34
-17.1% YoY
|
33.34
33.34 – 33.34
+0.0% YoY
|
32.31
32.31 – 32.31
-3.1% YoY
|
36.51
36.51 – 36.51
+13.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.61M | 0.06% |
| 2 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 52.9K | 0.48% |
| 3 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 119.3K | 0.26% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 5.89M | 0.06% |
| 5 | Vanguard ESG International Stock ETF VSGX | 0.00% | 84.0K | 0.10% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.00% | 6.53M | 0.05% |
| 7 | Vanguard ESG Global All Cap UCITS ETF (USD) Accumulating V3AA.L | 0.00% | 11.9K | 0.24% |
| 8 | Vanguard ESG Global All Cap UCITS ETF (USD) Distributing V3AL.L | 0.00% | 11.9K | 0.24% |
| 9 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 9.5K | 0.22% |
| 10 | Vanguard Total World Stock ETF VT | 0.00% | 350.2K | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bhavana Agrawal | Whole-Time Director & Chief Financial Officer | 23M | female |
| Ayush Kumar Agarwal | Business Unit Head of Biopharmaceutical Business Unit | — | male |
| Pankaj Jain | Legal Head | — | male |
| Praveen Akkinepally | MD & Director | — | male |
| Sandhya Amanna | Director of Legal | — | female |
| Smita Saha | Vice President of Human Resources | — | female |
| Srikanth S. | Site Lead, India Operations | — | male |
| Tanya Sanish | Company Secretary and Compliance Officer | — | female |
| Amarpreet Kaur Ahuja | Country HR Director | — | female |
| Vinay Sharma | Business Unit Head - Rare Disease unit | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ASTRAZEN.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
